{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:55:28Z","timestamp":1791114928812,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.4158\/ep09295.cr","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T21:36:13Z","timestamp":1263504973000},"page":"441-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sustained Remission with the Kinase Inhibitor Sorafenib in Stage IV Metastatic Adrenocortical Carcinoma"],"prefix":"10.1016","volume":"16","author":[{"given":"Charles","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP09295.CR_bb0010","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/jc.2008-2291","article-title":"Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review","volume":"94","author":"Golden","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09295.CR_bb0015","first-page":"99","article-title":"Adrenocortical cancer treatment","volume":"71","author":"Patalano","year":"2009","journal-title":"Horm Res"},{"key":"10.4158\/EP09295.CR_bb0020","series-title":"Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumors. Vol 8","first-page":"136","author":"Delellis","year":"2004"},{"key":"10.4158\/EP09295.CR_bb0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MED.0b013e3282fdf4c0","article-title":"Adjunctive treatment of adrenocortical carcinoma","volume":"15","author":"Terzolo","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.4158\/EP09295.CR_bb0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.4158\/EP09295.CR_bb0035","unstructured":"ClinicalTrials.gov Web site. Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRMACT). Available at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00094497"},{"key":"10.4158\/EP09295.CR_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14728214.13.3.497","article-title":"Emerging drugs for adrenocortical carcinoma","volume":"13","author":"Berruti","year":"2008","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.4158\/EP09295.CR_bb0045","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09295.CR_bb0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/jcp.2007.050625","article-title":"Pathological and molecular features of adrenocortical carcinoma: An update","volume":"61","author":"Volante","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.4158\/EP09295.CR_bb0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0167-4889(02)00316-6","article-title":"Molecular mechanisms of cytokine receptor activation","volume":"1592","author":"Gr\u00f6tzinger","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.4158\/EP09295.CR_bb0060","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.4158\/EP09295.CR_bb0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jjco\/hyn146","article-title":"Metastatic adrenocortical carcinoma treated with sunitinib: A case report","volume":"39","author":"Lee","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.4158\/EP09295.CR_bb0070","doi-asserted-by":"crossref","unstructured":"Negrier S, J\u00e4ger E, Porta C, et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2009;Sep 12. [Epub ahead of print].","DOI":"10.1007\/s12032-009-9303-z"},{"key":"10.4158\/EP09295.CR_bb0075","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09295.CR_bb0080","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/07435800009048610","article-title":"Expression of vascular endothelial growth factor in human adrenals","volume":"26","author":"Heikkil\u00e4","year":"2000","journal-title":"Endocr Res"},{"key":"10.4158\/EP09295.CR_bb0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1530\/eje.0.1500345","article-title":"Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours","volume":"150","author":"Zacharieva","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09295.CR_bb0090","first-page":"4734","article-title":"Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: Correlation with genotypic alterations","volume":"85","author":"de Fraipont","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09295.CR_bb0095","first-page":"9","article-title":"Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours","volume":"35","author":"Kolomecki","year":"2001","journal-title":"Endocr Regul"},{"key":"10.4158\/EP09295.CR_bb0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jc.2005-1739","article-title":"Emerging treatment strategies for adrenocortical carcinoma: A new hope","volume":"91","author":"Kirschner","year":"2006","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20416209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20416209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/G4067H83X77180PH.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:40Z","timestamp":1761515440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20416209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1530891X20416209"],"URL":"https:\/\/doi.org\/10.4158\/ep09295.cr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained Remission with the Kinase Inhibitor Sorafenib in Stage IV Metastatic Adrenocortical Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP09295.CR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}